Fisher Scientific International Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fisher Scientific International Inc.
Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology
The lesson that entrepreneurs and VCs seem to be taking from the fast-paced ophthalmology sector is the need for shorter development time frames and clinical candidates with reduced risk. Among others, MacuSight, Danube, and Lux, profiled here, are to one extent or another revisiting the existing pharmacopeia to test ophthalmic indications for existing compounds.
Deal Statistics Quarterly, Q2 2006
In this issue, we present another installment of our quarterly review of dealmaking-for April-June 2006. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.
Deal Statistics Quarterly, Q1 2006
In this issue, we present another installment of our quarterly review of dealmaking-for January-March 2006. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.
Molecular Diagnostics--From Tools to Tests
Instrument makers have made big money off the genomics revolution. But as the research market slows, companies are looking for new business opportunities. One area ripe for development: the molecular diagnostics market.
- In Vitro Diagnostics
- Medical Devices
- Research, Analytical Equipment & Supplies
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.